GlassScriptPhysician profile
Howard W Fellows
NPI 1659365526
$1,720.63
in general payments reported to CMS, 2019-2025
25 companies · $88.40 in 2025
The $88.40 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,097 · 2020: $144 · 2021: $61.47 · 2022: $168 · 2023: $90.43 · 2024: $70.82 · 2025: $88.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $194 · Education: $55.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $193.68 |
| Education | $55.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $320.30 | 2019-2024 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $293.34 | 2019-2023 | Opdivo |
| Merck Sharp & Dohme LLC | $148.00 | 2019-2020 | |
| Pfizer INC. | $129.97 | 2019-2022 | |
| Amgen INC. | $129.67 | 2019-2022 | |
| Janssen Biotech, INC. | $128.72 | 2019-2025 | Tecvayli |
| Genentech USA, INC. | $73.94 | 2019-2020 | |
| Celgene Corporation | $61.45 | 2019-2024 | Reblozyl |
| Tesaro, INC. | $54.44 | 2019 | |
| Gilead Sciences, INC. | $47.45 | 2019-2021 | |
| Incyte Corporation | $47.28 | 2020-2025 | Monjuvi, Zynyz |
| Teva Pharmaceuticals USA, INC. | $36.77 | 2019 | |
| Lilly USA, LLC | $29.95 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.87 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.34 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Morphosys, US INC. | $25.00 | 2022 | |
| Clovis Oncology, INC. | $21.96 | 2019 | |
| Rigel Pharmaceuticals, INC. | $19.70 | 2019 | |
| Astellas Pharma US INC | $18.95 | 2019 | |
| Verastem, INC. | $15.18 | 2019 | |
| Seagen INC. | $14.90 | 2020 | |
| Acrotech Biopharma INC. | $13.93 | 2021 | |
| Sun Pharmaceutical Industries INC. | $13.39 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.23 | 2019 | |
| Eisai INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Fellows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.